Abstract
The role of palmitoylethanolamide (PEA) in the regulation of complex systems involved in the inflammatory response, pruritus, neurogenic and neuropathic pain is well understood. Growing evidence indicates that this Nacylethanolamine also exerts neuroprotective effects within the central nervous system (CNS), i.e. in spinal cord and traumatic brain injuries and in age-related pathological processes. PEA is abundant in the CNS, and is produced by glial cells. Several studies show that administering PEA during the first few hours after injury significantly limits CNS damage, reduces loss of neuronal tissue and improves functional recovery. PEA appears to exert its protective effect by decreasing the development of cerebral edema, down-regulating the inflammatory cascade, and limiting cellular necrosis and apoptosis. All these are plausible mechanisms of neuroprotection. This review provides an overview of current knowledge of PEA effect on glial functions in the brain and how targeting glial-specific pathways might ultimately impact the development of therapies for clinical management of neurodegenerative disorders. The diverse signaling mechanisms are also summarized.
Keywords: Glial cells, N-acylethanolamine, neuroprotection, spinal cord
CNS & Neurological Disorders - Drug Targets
Title:Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries
Volume: 12 Issue: 1
Author(s): Emanuela Esposito and Salvatore Cuzzocrea
Affiliation:
Keywords: Glial cells, N-acylethanolamine, neuroprotection, spinal cord
Abstract: The role of palmitoylethanolamide (PEA) in the regulation of complex systems involved in the inflammatory response, pruritus, neurogenic and neuropathic pain is well understood. Growing evidence indicates that this Nacylethanolamine also exerts neuroprotective effects within the central nervous system (CNS), i.e. in spinal cord and traumatic brain injuries and in age-related pathological processes. PEA is abundant in the CNS, and is produced by glial cells. Several studies show that administering PEA during the first few hours after injury significantly limits CNS damage, reduces loss of neuronal tissue and improves functional recovery. PEA appears to exert its protective effect by decreasing the development of cerebral edema, down-regulating the inflammatory cascade, and limiting cellular necrosis and apoptosis. All these are plausible mechanisms of neuroprotection. This review provides an overview of current knowledge of PEA effect on glial functions in the brain and how targeting glial-specific pathways might ultimately impact the development of therapies for clinical management of neurodegenerative disorders. The diverse signaling mechanisms are also summarized.
Export Options
About this article
Cite this article as:
Esposito Emanuela and Cuzzocrea Salvatore, Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries, CNS & Neurological Disorders - Drug Targets 2013; 12 (1) . https://dx.doi.org/10.2174/1871527311312010010
DOI https://dx.doi.org/10.2174/1871527311312010010 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy
Current Neuropharmacology Therapeutic Effects of Rivastigmine and Alfa-Lipoic Acid Combination in the Charles Bonnet Syndrome: Electroencephalography Correlates
Current Clinical Pharmacology Recent Software Developments and Applications in Functional Imaging
Current Pharmaceutical Biotechnology Neuroprotective Properties of Erythropoietin in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Cardiac-Specific Expression of the Hepatocyte Growth Factor (HGF) Under the Control of a TnIc Promoter Confers a Heart Protective Effect After Myocardial Infarction (MI)
Current Gene Therapy Recent Patents Relating to siRNAs and Therapeutic Strategies for Genetic Diseases
Recent Patents on DNA & Gene Sequences Conference Report (The XVth International Symposium of Brain Edema and Cellular Injury)
CNS & Neurological Disorders - Drug Targets Brain Drug Delivery Systems for the Stroke Intervention and Recovery
Current Pharmaceutical Design The Contribution of Proteinase-Activated Receptors to Intracellular Signaling, Transcellular Transport and Autophagy in Alzheimer´s Disease
Current Alzheimer Research Biosynthesis and Biological Activities of In Vitro Derived Solasodine Glycoalkaloids from <i>Solanum laciniatum</i>
The Natural Products Journal Potential Role of Natural Compounds Against Skin Aging
Current Medicinal Chemistry Vasopressin in Health and Disease with a Focus on Affective Disorders
Central Nervous System Agents in Medicinal Chemistry Propranolol Safety Profile in Children
Current Drug Safety Nanoparticle-Mediated Drug Delivery: Blood-Brain Barrier as the Main Obstacle to Treating Infectious Diseases in CNS
Current Pharmaceutical Design Acid Sensing Ion Channels and Acid Nociception
Current Pharmaceutical Design NLRP3 Is Involved in Ischemia/Reperfusion Injury
CNS & Neurological Disorders - Drug Targets Stem Cells as a Novel Tool for Drug Screening and Treatment of Degenerative Diseases
Current Pharmaceutical Design Sesbania: A Prospective Candidate to be Excavated for Anticancer Drugs
The Natural Products Journal Glutathione-Related Factors and Oxidative Stress in Autism, A Review
Current Medicinal Chemistry The Variable Presentations of Glycogen Storage Disease Type IV: A Review of Clinical, Enzymatic and Molecular Studies
Current Molecular Medicine